Melanoma Vaccines
Malignant melanoma is the most dangerous type of skin cancer. Its annual incidence rates have been growing throughout recent decades in fair-skinned populations [1]. Risk factors include skin type, multiple nevi and, above all, exposure to sunlight, especially sunburns in childhood [2]. In recent years advances in melanoma treatment were expected to be based on the development of immunotherapeutic concepts [3].
BioLife Science is currently developing peptide-based melanoma vaccines using the mimotope technology employed for MimoVac® breast cancer vaccines.
References
-
Marks R.:
Epidemiology of melanoma.
Clin. Exp. Dermatol. 25(6), 459-463 (2000) [PubMed] -
Green A, Whiteman D, Frost C, Battistutta D.:
Sun exposure, skin cancers and related skin conditions.
J. Epidemiol. 9(6 Suppl.), S7-S13 (1999) [PubMed] -
Jager D, Jager E, Knuth A.:
Vaccination for malignant melanoma: recent developments.
Oncology 60(1), 1-7 (2001) [PubMed]